| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 78/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Febuxostat is a new generation of xanthine oxidase inhibitor developed by Teijin Corporation in Japan. It is clinically used to treat hyperuricemia (gout) and has a completely different structure from the xanthine oxidase inhibitor drug developed 40 years ago. It is a novel and efficient non purine xanthine oxidase selective inhibitor. Xanthine oxidase is a key enzyme that promotes uric acid production in Chemicalbook. Febuxostat can reduce the uric acid levels in the blood of gout patients with hyperuricemia. Clinical studies have shown that this product is safe and effective. It is metabolized by the liver and does not rely on renal excretion. Therefore, it is not necessary to reduce the dosage for patients with moderate to severe liver and kidney dysfunction. The dosage is once daily, 40mg or 80mg, and is not recommended for treating gout patients without hyperuricemia.
| Analysi | Specifications | |
| Assay | ≥99% | |
| Appearance | White powder | |
| Loss on Drying | ≤1.0% | |
| Ash | ≤1.0% | |
| As | ≤2.0ppm | |
| Pb | ≤2.0ppm | |
| Insoluble impurity content | ≤0.05% | |
| Total Plate Count | ≤1000 cfu/g | |
| Yeast &. Mold | ≤100 cfu/g | |
| E.Coli | Negative | |
| Salmonella | Negative | |
| Conclusion |
Conform USP Standard.
|
|
| Storage condition |
Store in cool & dry place, Keep away from strong light and heat.
|
|
| Shelf life |
2 years when properly stored.
|
|
){kind=link}